• DOMA Perpetual, holder of about 7.5% of Pacira BioSciences shares, launched a proxy fight ahead of June 9 annual meeting, urging holders to vote FOR its three independent director nominees on its WHITE proxy card.
• Activist called for removal of CEO Frank Lee, citing weak revenue growth versus 5x30 plan targets, rising expenses, rising stock-based compensation, negative net income of USD 93 million over last two years.
• Campaign focused on EXPAREL patent litigation risk, arguing prior settlement could cede over 30% of US supply to a generic entrant by 2033, threatening product that activist said accounts for about 80% of revenue.
• DOMA pressed board to explore strategic alternatives, including a sale, framing it as a more certain path than continued litigation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605131058PR_NEWS_USPR_____FL58649) on May 13, 2026, and is solely responsible for the information contained therein.